NASDAQ
10.11.26 | 22:00
18,710 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 22.10. | Arcus Biosciences prices $250M public offering at $17.50 per share | 1 | Seeking Alpha | ||
| 22.10. | Arcus Biosciences prices $250 million stock offering at $17.50 | 1 | Investing.com | ||
| 22.10. | Arcus Biosciences slides 20% on stock offering, kidney-cancer data | 2 | Seeking Alpha | ||
| 21.10. | Arcus Biosciences kündigt öffentliche Aktienplatzierung an | 3 | Investing.com Deutsch | ||
| 21.10. | Arcus Biosciences launches public offering of common stock | 1 | Investing.com | ||
| 21.10. | Arcus Biosciences announces public stock offering | 1 | Seeking Alpha | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 21.10. | Truist raises Arcus Biosciences stock price target on drug data | 1 | Investing.com | ||
| 20.10. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10. | William Blair initiates Arcus Biosciences stock with outperform rating | 1 | Investing.com | ||
| 16.10. | William Blair nimmt Arcus Biosciences mit "Outperform" auf - 119 % Kurspotenzial gesehen | 1 | Investing.com Deutsch | ||
| 14.10. | Arcus Biosciences: JPMorgan initiiert Coverage mit "Overweight" - Kursziel 41 $ | 3 | Investing.com Deutsch | ||
| 14.10. | JPMorgan initiates Arcus Biosciences stock at Overweight, $41 target | 1 | Investing.com | ||
| 22.09. | Cantor Fitzgerald reiterates Arcus Biosciences stock rating | 1 | Investing.com | ||
| 16.09. | Arcus Biosciences: Aktie legt nach Kaufempfehlung von TD Cowen zu | 2 | Investing.com Deutsch | ||
| 16.09. | Arcus Biosciences stock initiated at Buy by TD Cowen on RCC drug | 1 | Investing.com | ||
| 10.09. | Arcus Biosciences: Casdatifan-Strategie auf der Cantor Global Healthcare Conference im Fokus | 1 | Investing.com Deutsch | ||
| 09.09. | Arcus Biosciences auf dem Citi-Gipfel: Casdatifan-Daten stehen im Fokus | 2 | Investing.com Deutsch | ||
| 08.09. | Truist raises Arcus Biosciences stock price target on trial data | 1 | Investing.com | ||
| 14.08. | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | 19 | Insider Monkey |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
ARCUS BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 18,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.